Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI). We report here a real-life single-center series of 49 consecutive patients with relapsed and refr...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2019-06, Vol.98 (6), p.1441-1447 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1447 |
|---|---|
| container_issue | 6 |
| container_start_page | 1441 |
| container_title | Annals of hematology |
| container_volume | 98 |
| creator | Trudel, Sabrina Tessoulin, Benoît Jullien, Maxime Blin, Nicolas Gastinne, Thomas Mahé, Béatrice Dubruille, Viviane Bonnet, Antoine Lok, Anne Chevallier, Patrice Peterlin, Pierre Garnier, Alice Guillaume, Thierry Le Bourgeois, Amandine Le Gouill, Steven Moreau, Philippe Touzeau, Cyrille |
| description | Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI). We report here a real-life single-center series of 49 consecutive patients with relapsed and refractory MM treated with the triplet pomalidomide cyclophosphamide dexamethasone (PCD) combination. The median of prior lines of therapy was 3 and all patients were previously exposed to proteasome inhibitors and lenalidomide. The overall response rate was 76%, including 27% very good partial response or better. With a median follow-up of 16 months, the median progression-free survival (PFS) was 7.3 months and the median overall survival was not reached. Regarding safety, most frequent toxicity was hematologic, including 37% grade 3–4 cytopenias. Nine patients (18%) discontinued therapy due to adverse event. Our study confirms that PCD combination is feasible and results in favorable response rate and PFS in comparison with pomalidomide dexamethasone alone. |
| doi_str_mv | 10.1007/s00277-019-03649-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2193168123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2193168123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-39a9c337b5b6cc1c18162f9bbf281b5e0d9b61e7098f672206e43673905a327e3</originalsourceid><addsrcrecordid>eNp9kc-O1SAUh4nRONfRF3BhSNy4EOcAbSnuJhP_JZPoQtcNpadzmdBSgRr7NL6qXDtq4kI2J4HvfAf4EfKUwysOoC4SgFCKAdcMZFNpJu-RA6-kYFC31X1yAC01q8s6I49SugXgoq3EQ3ImoVVVW_MD-fEpTMa7IUxuwJfUbtaH5RjScjT7jpkHOuB3M2E-mhRmpGOINKI3S8LhIuIYjc0hbnRafXaLRzpt6IuVLiY7nHOibqamtBjPvBuRJszZzTevy2Yq1SOzBcOTNccyGm123wqW12F7TB6Mxid8clfPyZe3bz5fvWfXH999uLq8ZlaqOjOpjbZSqr7uG2u55S1vxKj7fhQt72uEQfcNRwW6HRslBDRYyUZJDbWRQqE8Jy927xLD1xVT7iaXLHpvZgxr6gTXkjctF7Kgz_9Bb8Ma53K7E1WIugYolNgpW56Uyjd1S3STiVvHoTvF1-3xdSW-7ld83Un97E699hMOf1p-51UAuQOpHM03GP_O_o_2JyxXqEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2191235500</pqid></control><display><type>article</type><title>Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study</title><source>SpringerLink Journals - AutoHoldings</source><creator>Trudel, Sabrina ; Tessoulin, Benoît ; Jullien, Maxime ; Blin, Nicolas ; Gastinne, Thomas ; Mahé, Béatrice ; Dubruille, Viviane ; Bonnet, Antoine ; Lok, Anne ; Chevallier, Patrice ; Peterlin, Pierre ; Garnier, Alice ; Guillaume, Thierry ; Le Bourgeois, Amandine ; Le Gouill, Steven ; Moreau, Philippe ; Touzeau, Cyrille</creator><creatorcontrib>Trudel, Sabrina ; Tessoulin, Benoît ; Jullien, Maxime ; Blin, Nicolas ; Gastinne, Thomas ; Mahé, Béatrice ; Dubruille, Viviane ; Bonnet, Antoine ; Lok, Anne ; Chevallier, Patrice ; Peterlin, Pierre ; Garnier, Alice ; Guillaume, Thierry ; Le Bourgeois, Amandine ; Le Gouill, Steven ; Moreau, Philippe ; Touzeau, Cyrille</creatorcontrib><description>Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI). We report here a real-life single-center series of 49 consecutive patients with relapsed and refractory MM treated with the triplet pomalidomide cyclophosphamide dexamethasone (PCD) combination. The median of prior lines of therapy was 3 and all patients were previously exposed to proteasome inhibitors and lenalidomide. The overall response rate was 76%, including 27% very good partial response or better. With a median follow-up of 16 months, the median progression-free survival (PFS) was 7.3 months and the median overall survival was not reached. Regarding safety, most frequent toxicity was hematologic, including 37% grade 3–4 cytopenias. Nine patients (18%) discontinued therapy due to adverse event. Our study confirms that PCD combination is feasible and results in favorable response rate and PFS in comparison with pomalidomide dexamethasone alone.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-019-03649-3</identifier><identifier>PMID: 30874851</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Hematology ; Medicine ; Medicine & Public Health ; Multiple myeloma ; Oncology ; Original Article ; Response rates ; Steroids</subject><ispartof>Annals of hematology, 2019-06, Vol.98 (6), p.1441-1447</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>Annals of Hematology is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-39a9c337b5b6cc1c18162f9bbf281b5e0d9b61e7098f672206e43673905a327e3</citedby><cites>FETCH-LOGICAL-c375t-39a9c337b5b6cc1c18162f9bbf281b5e0d9b61e7098f672206e43673905a327e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-019-03649-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-019-03649-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30874851$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trudel, Sabrina</creatorcontrib><creatorcontrib>Tessoulin, Benoît</creatorcontrib><creatorcontrib>Jullien, Maxime</creatorcontrib><creatorcontrib>Blin, Nicolas</creatorcontrib><creatorcontrib>Gastinne, Thomas</creatorcontrib><creatorcontrib>Mahé, Béatrice</creatorcontrib><creatorcontrib>Dubruille, Viviane</creatorcontrib><creatorcontrib>Bonnet, Antoine</creatorcontrib><creatorcontrib>Lok, Anne</creatorcontrib><creatorcontrib>Chevallier, Patrice</creatorcontrib><creatorcontrib>Peterlin, Pierre</creatorcontrib><creatorcontrib>Garnier, Alice</creatorcontrib><creatorcontrib>Guillaume, Thierry</creatorcontrib><creatorcontrib>Le Bourgeois, Amandine</creatorcontrib><creatorcontrib>Le Gouill, Steven</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>Touzeau, Cyrille</creatorcontrib><title>Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI). We report here a real-life single-center series of 49 consecutive patients with relapsed and refractory MM treated with the triplet pomalidomide cyclophosphamide dexamethasone (PCD) combination. The median of prior lines of therapy was 3 and all patients were previously exposed to proteasome inhibitors and lenalidomide. The overall response rate was 76%, including 27% very good partial response or better. With a median follow-up of 16 months, the median progression-free survival (PFS) was 7.3 months and the median overall survival was not reached. Regarding safety, most frequent toxicity was hematologic, including 37% grade 3–4 cytopenias. Nine patients (18%) discontinued therapy due to adverse event. Our study confirms that PCD combination is feasible and results in favorable response rate and PFS in comparison with pomalidomide dexamethasone alone.</description><subject>Hematology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multiple myeloma</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Response rates</subject><subject>Steroids</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc-O1SAUh4nRONfRF3BhSNy4EOcAbSnuJhP_JZPoQtcNpadzmdBSgRr7NL6qXDtq4kI2J4HvfAf4EfKUwysOoC4SgFCKAdcMZFNpJu-RA6-kYFC31X1yAC01q8s6I49SugXgoq3EQ3ImoVVVW_MD-fEpTMa7IUxuwJfUbtaH5RjScjT7jpkHOuB3M2E-mhRmpGOINKI3S8LhIuIYjc0hbnRafXaLRzpt6IuVLiY7nHOibqamtBjPvBuRJszZzTevy2Yq1SOzBcOTNccyGm123wqW12F7TB6Mxid8clfPyZe3bz5fvWfXH999uLq8ZlaqOjOpjbZSqr7uG2u55S1vxKj7fhQt72uEQfcNRwW6HRslBDRYyUZJDbWRQqE8Jy927xLD1xVT7iaXLHpvZgxr6gTXkjctF7Kgz_9Bb8Ma53K7E1WIugYolNgpW56Uyjd1S3STiVvHoTvF1-3xdSW-7ld83Un97E699hMOf1p-51UAuQOpHM03GP_O_o_2JyxXqEg</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Trudel, Sabrina</creator><creator>Tessoulin, Benoît</creator><creator>Jullien, Maxime</creator><creator>Blin, Nicolas</creator><creator>Gastinne, Thomas</creator><creator>Mahé, Béatrice</creator><creator>Dubruille, Viviane</creator><creator>Bonnet, Antoine</creator><creator>Lok, Anne</creator><creator>Chevallier, Patrice</creator><creator>Peterlin, Pierre</creator><creator>Garnier, Alice</creator><creator>Guillaume, Thierry</creator><creator>Le Bourgeois, Amandine</creator><creator>Le Gouill, Steven</creator><creator>Moreau, Philippe</creator><creator>Touzeau, Cyrille</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190601</creationdate><title>Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study</title><author>Trudel, Sabrina ; Tessoulin, Benoît ; Jullien, Maxime ; Blin, Nicolas ; Gastinne, Thomas ; Mahé, Béatrice ; Dubruille, Viviane ; Bonnet, Antoine ; Lok, Anne ; Chevallier, Patrice ; Peterlin, Pierre ; Garnier, Alice ; Guillaume, Thierry ; Le Bourgeois, Amandine ; Le Gouill, Steven ; Moreau, Philippe ; Touzeau, Cyrille</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-39a9c337b5b6cc1c18162f9bbf281b5e0d9b61e7098f672206e43673905a327e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Hematology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multiple myeloma</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Response rates</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trudel, Sabrina</creatorcontrib><creatorcontrib>Tessoulin, Benoît</creatorcontrib><creatorcontrib>Jullien, Maxime</creatorcontrib><creatorcontrib>Blin, Nicolas</creatorcontrib><creatorcontrib>Gastinne, Thomas</creatorcontrib><creatorcontrib>Mahé, Béatrice</creatorcontrib><creatorcontrib>Dubruille, Viviane</creatorcontrib><creatorcontrib>Bonnet, Antoine</creatorcontrib><creatorcontrib>Lok, Anne</creatorcontrib><creatorcontrib>Chevallier, Patrice</creatorcontrib><creatorcontrib>Peterlin, Pierre</creatorcontrib><creatorcontrib>Garnier, Alice</creatorcontrib><creatorcontrib>Guillaume, Thierry</creatorcontrib><creatorcontrib>Le Bourgeois, Amandine</creatorcontrib><creatorcontrib>Le Gouill, Steven</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>Touzeau, Cyrille</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trudel, Sabrina</au><au>Tessoulin, Benoît</au><au>Jullien, Maxime</au><au>Blin, Nicolas</au><au>Gastinne, Thomas</au><au>Mahé, Béatrice</au><au>Dubruille, Viviane</au><au>Bonnet, Antoine</au><au>Lok, Anne</au><au>Chevallier, Patrice</au><au>Peterlin, Pierre</au><au>Garnier, Alice</au><au>Guillaume, Thierry</au><au>Le Bourgeois, Amandine</au><au>Le Gouill, Steven</au><au>Moreau, Philippe</au><au>Touzeau, Cyrille</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>98</volume><issue>6</issue><spage>1441</spage><epage>1447</epage><pages>1441-1447</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI). We report here a real-life single-center series of 49 consecutive patients with relapsed and refractory MM treated with the triplet pomalidomide cyclophosphamide dexamethasone (PCD) combination. The median of prior lines of therapy was 3 and all patients were previously exposed to proteasome inhibitors and lenalidomide. The overall response rate was 76%, including 27% very good partial response or better. With a median follow-up of 16 months, the median progression-free survival (PFS) was 7.3 months and the median overall survival was not reached. Regarding safety, most frequent toxicity was hematologic, including 37% grade 3–4 cytopenias. Nine patients (18%) discontinued therapy due to adverse event. Our study confirms that PCD combination is feasible and results in favorable response rate and PFS in comparison with pomalidomide dexamethasone alone.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30874851</pmid><doi>10.1007/s00277-019-03649-3</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2019-06, Vol.98 (6), p.1441-1447 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2193168123 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Hematology Medicine Medicine & Public Health Multiple myeloma Oncology Original Article Response rates Steroids |
| title | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T17%3A54%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pomalidomide,%20cyclophosphamide,%20and%20dexamethasone%20for%20relapsed/refractory%20multiple%20myeloma%20patients%20in%20a%20real-life%20setting:%20a%20single-center%20retrospective%20study&rft.jtitle=Annals%20of%20hematology&rft.au=Trudel,%20Sabrina&rft.date=2019-06-01&rft.volume=98&rft.issue=6&rft.spage=1441&rft.epage=1447&rft.pages=1441-1447&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-019-03649-3&rft_dat=%3Cproquest_cross%3E2193168123%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2191235500&rft_id=info:pmid/30874851&rfr_iscdi=true |